Group 1 - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance for the clinical trial application of GS3-007a dry suspension from the National Medical Products Administration [1] - GS3-007a is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug, intended for the treatment of idiopathic short stature (ISS) [1] - ISS is a common pediatric endocrine disorder defined as a height below -2 standard deviations (SD) for age, sex, and racial reference values, excluding other causes of short stature [1] Group 2 - The GS3-007a dry suspension offers a daily oral administration option that stimulates endogenous growth hormone release, providing more treatment choices for short children in need of growth promotion [1]